Segment, Geographic and Other Revenue Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended				9 Months Ended
	Sep. 29, 2013		Sep. 30, 2012		Sep. 29, 2013		Sep. 30, 2012
Segment Reporting Information [Line Items]
Revenues	$ 12,643		$ 12,953		$ 38,026		$ 40,766
R&D Expenses	1,627	[1]	1,887	[1]	4,867	[1]	5,461	[1]
Earnings(a)	3,573	[2]	2,806	[2]	12,655	[2]	9,165	[2]
Primary Care [Member]
Segment Reporting Information [Line Items]
Revenues	3,259	[3]	3,610	[3]	9,830	[3]	11,725	[3]
R&D Expenses	245	[3]	247	[3]	682	[3]	739	[3]
Earnings(a)	1,917	[2],[3]	2,112	[2],[3]	6,002	[2],[3]	7,399	[2],[3]
Specialty Care And Oncology [Member]
Segment Reporting Information [Line Items]
Revenues	3,756		3,735		11,069		11,423
R&D Expenses	326		345		1,047		1,044
Earnings(a)	2,660	[2]	2,630	[2]	7,670	[2]	7,883	[2]
Established Products and Emerging Markets [Member]
Segment Reporting Information [Line Items]
Revenues	4,727	[4]	4,772	[4]	14,499	[4]	15,173	[4]
R&D Expenses	95	[4]	84	[4]	264	[4]	223	[4]
Earnings(a)	2,680	[2],[4]	2,673	[2],[4]	8,303	[2],[4]	8,926	[2],[4]
Reportable Segments [Member]
Segment Reporting Information [Line Items]
Revenues	11,742		12,117		35,398		38,321
R&D Expenses	666		676		1,993		2,006
Earnings(a)	7,257	[2]	7,415	[2]	21,975	[2]	24,208	[2]
Consumer Healthcare and other business activities [Member]
Segment Reporting Information [Line Items]
Revenues	834	[5]	836	[5]	2,561	[5]	2,445	[5]
R&D Expenses	734	[5]	933	[5]	2,113	[5]	2,322	[5]
Earnings(a)	(491)	[2],[5]	(693)	[2],[5]	(1,410)	[2],[5]	(1,721)	[2],[5]
Corporate [Member]
Segment Reporting Information [Line Items]
Revenues	0	[6]	0	[6]	0	[6]	0	[6]
R&D Expenses	220	[6]	217	[6]	639	[6]	705	[6]
Earnings(a)	(1,369)	[2],[6]	(1,359)	[2],[6]	(4,194)	[2],[6]	(4,700)	[2],[6]
Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues	0	[7]	0	[7]	0	[7]	0	[7]
R&D Expenses	1	[7]	(1)	[7]	(1)	[7]	(4)	[7]
Earnings(a)	(960)	[2],[7]	(1,127)	[2],[7]	(3,287)	[2],[7]	(3,713)	[2],[7]
Acquisition-related Costs [Member]
Segment Reporting Information [Line Items]
Revenues	0	[8]	0	[8]	0	[8]	0	[8]
R&D Expenses	0	[8]	0	[8]	0	[8]	5	[8]
Earnings(a)	(61)	[2],[8]	(237)	[2],[8]	(264)	[2],[8]	(638)	[2],[8]
Certain significant items [Member]
Segment Reporting Information [Line Items]
Revenues	67	[9]	0	[9]	67	[9]	0	[9]
R&D Expenses	1	[9]	47	[9]	104	[9]	386	[9]
Earnings(a)	(744)	[2],[9]	(1,052)	[2],[9]	180	[2],[9]	(3,784)	[2],[9]
Other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues	0	[10]	0	[10]	0	[10]	0	[10]
R&D Expenses	5	[10]	15	[10]	19	[10]	41	[10]
Earnings(a)	$ (59)	[10],[2]	$ (141)	[10],[2]	$ (345)	[10],[2]	$ (487)	[10],[2]

[1] Excludes amortization of intangible assets, except as disclosed in Note 9B. Goodwill and Other Intangible Assets: Other Intangible Assets.

[2] Income from continuing operations before provision for taxes on income.

[3] Revenues and Earnings from the Primary Care segment decreased in the three and nine months ended September 29, 2013 as compared to the prior year, and Earnings as a percentage of revenues for the nine months ended September 29, 2013 also declined, primarily due to the loss of exclusivity for Lipitor in developed Europe and Australia; the subsequent shift in the reporting of Lipitor in those markets to the Established Products business unit; the losses of exclusivity of certain other products in various markets; lower Alliance revenues from Spiriva due to the ongoing expiration of the Spiriva collaboration in certain countries; and the termination of the co-promotion agreement for Aricept in Japan in December 2012. Earnings as a percentage of revenues increased for the three months ended September 29, 2013 primarily due to market growth of Lyrica as well as mid-year price increases.

[4] Revenues from the Established Products and Emerging Markets segment decreased in the three and nine months ended September 29, 2013, and Earnings from the Established Products and Emerging Markets segment decreased in the nine months ended September 29, 2013, as compared to the prior year, primarily due to the continued erosion of branded Lipitor in the U.S. and Japan, partially offset by the addition of products in certain markets that shifted to the Established Products unit from other business units beginning January 1, 2013 and strong volume growth in China. Earnings as a percentage of revenue increased in the three months ended September 29, 2013 as compared to the prior year due to Lipitor and Norvasc growth in China. Earnings as a percentage of revenue decreased in the nine months ended September 29, 2013 as compared to the prior year due to the change in the mix of products.

[5] Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the R&D costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

[6] Corporate for R&D expenses includes, among other things, administration expenses and compensation expenses associated with our research and development activities, and for Earnings includes, among other things, administration expenses, interest income/(expense) and certain compensation and other costs not charged to our operating segments.

[7] Purchase accounting adjustments include certain charges related to the fair value adjustments to inventory, intangible assets and property, plant and equipment.

[8] Acquisition-related costs can include costs associated with acquiring, integrating and restructuring newly acquired businesses, such as transaction costs, integration costs, restructuring charges and additional depreciation associated with asset restructuring. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.

[9] Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. For Revenues in the third quarter and first nine months of 2013, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Note 2B. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investments: Divestitures.For Earnings in the third quarter of 2013, certain significant items includes: (i) income related to our transitional manufacturing and supply agreements with Zoetis of $10 million, (ii) certain asset impairments and related charges of $440 million, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $262 million, (iv) other charges of $43 million and (v) costs associated with a patent litigation settlement of $9 million. For additional information, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments, Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.For Earnings in the third quarter of 2012, certain significant items includes: (i) charges for certain legal matters of $723 million, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $263 million, (iii) costs associated with the separation of Zoetis of $32 million, (iv) certain asset impairment charges of $17 million and (v) other charges of $17 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.For Earnings in the first nine months of 2013, certain significant items includes: (i) patent litigation settlement income of $1.3 billion, (ii) the gain associated with the transfer of certain product rights to our equity-method investment in China of $459 million, (iii) net credits for certain legal matters of $99 million, (iv) income related to our transitional manufacturing and supply agreements with Zoetis of $10 million, (v) certain asset impairments and related charges of $929 million, (vi) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $662 million, (vii) other charges of $121 million and (viii) costs associated with the separation of Zoetis of $18 million. For additional information, see Note 2D. Acquisitions, Divestitures, Collaborative Arrangement and Equity-Method Investments: Equity-Method Investments, Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.For Earnings in the first nine months of 2012, certain significant items includes: (i) charges for certain legal matters of $2.0 billion, (ii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $1.1 billion, (iii) certain asset impairment charges of $506 million, (iv) costs associated with the separation of Zoetis of $93 million and (v) other charges of $55 million. For additional information, see Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives and Note 4. Other (Income)/Deductions––Net.For R&D in all periods presented, certain significant items primarily reflect additional depreciation––asset restructuring and implementation costs.

[10] Includes overhead expenses associated with our manufacturing and commercial operations not directly attributable to an operating segment.